Antiphospholipid Syndrome: A Clinical Perspective

0
0
0

Antiphospholipid Syndrome: A Clinical Perspective

Antiphospholipid syndrome (APS) is a systemic autoimmune thromboinflammatory disorder characterized by arterial, venous, or microvascular thrombosis, obstetric complications, and a persistent presence of antiphospholipid antibodies (aPL). The syndrome manifests through heterogeneous clinical phenotypes, including thrombotic events, pregnancy morbidity, and non-criteria manifestations such as thrombocytopenia, livedo reticularis, and cognitive dysfunction. APS is classified into primary APS (occurring in isolation) and secondary APS (associated with systemic lupus erythematosus or other autoimmune diseases). A rare, life-threatening subset—catastrophic APS (CAPS)—involves widespread microvascular thrombosis leading to multi-organ failure. With a population prevalence of approximately 50 per 100,000, APS poses significant clinical challenges due to its diverse presentations and the need for tailored therapeutic strategies.

Pathophysiology and Emerging Mechanisms

APS pathogenesis revolves around aPL, which target phospholipid-binding proteins such as β2-glycoprotein I (β2GPI), prothrombin, and annexins. These antibodies activate endothelial cells, monocytes, and platelets, disrupt anticoagulant pathways, and promote a prothrombotic state. Recent studies highlight the role of neutrophil extracellular traps (NETs) in APS. Neutrophils exposed to aPL release NETs enriched in citrullinated histones and DNA, which propagate thrombin generation and inflammatory responses. In murine models, NET inhibition reduces thrombosis, suggesting therapeutic potential in targeting NETosis.

MicroRNAs (miRNAs) also contribute to APS pathogenesis. Reduced levels of miR-19b and miR-20a in APS monocytes correlate with increased tissue factor expression, enhancing thrombotic risk. Additionally, APS patients exhibit upregulated P-selectin glycoprotein ligand-1 (PSGL-1), which facilitates leukocyte adhesion and thrombus formation. Complement activation, particularly through C5a, exacerbates placental injury and thrombosis, as evidenced by protective effects of complement inhibitors in experimental models.

Primary Thrombosis Prophylaxis

Asymptomatic aPL carriers present a clinical dilemma, as transient aPL positivity (common during infections) does not correlate with thrombotic risk. Persistent, high-titer aPL—defined by medium/high anticardiolipin (aCL) IgG/IgM, anti-β2GPI IgG/IgM, or lupus anticoagulant (LA) positivity on two occasions ≥12 weeks apart—warrant risk stratification. Observational studies estimate an annual thrombosis incidence of <1% in low-risk carriers but 5.3% in triple-positive (aCL, anti-β2GPI, and LA) patients.

Aspirin remains controversial for primary prophylaxis. The APLASA trial showed no benefit of low-dose aspirin (81 mg/day) over placebo in preventing first thrombotic events (hazard ratio [HR] 1.04). However, subgroup analyses suggest aspirin may reduce risk in high-risk aPL carriers (e.g., triple-positive profiles or concomitant SLE). Hydroxychloroquine (HCQ), known to attenuate aPL-mediated endothelial activation, reduces thrombosis risk in SLE patients with aPL. Statins, such as fluvastatin, lower proinflammatory and prothrombotic biomarkers (e.g., tissue factor, IL-6) in APS monocytes, highlighting their potential as adjunctive therapy.

Secondary Thrombosis Prophylaxis

Vitamin K antagonists (VKAs), particularly warfarin (target INR 2.0–3.0), remain the cornerstone for preventing recurrent thrombosis. High-intensity warfarin (INR 3.1–4.0) offers no superior efficacy but increases bleeding risk. Direct oral anticoagulants (DOACs) like rivaroxaban are discouraged in APS, especially in arterial thrombosis or triple-positive patients. The RIVAPS trial demonstrated higher thrombotic events with rivaroxaban versus warfarin (HR 7.4), prompting early trial termination. For warfarin-refractory cases, low-molecular-weight heparin (LMWH) or combined VKA-aspirin regimens may be considered.

Obstetric Management

APS-associated pregnancy morbidity includes recurrent early miscarriages, fetal death ≥10 weeks, or preterm delivery due to severe preeclampsia. Management strategies vary by clinical history:

  1. Asymptomatic aPL carriers: Low-dose aspirin (75–81 mg/day) is optional for high-risk profiles (e.g., triple positivity).
  2. Recurrent first-trimester loss: Combining aspirin with prophylactic heparin/LMWH improves live birth rates (70–80% success).
  3. Prior preeclampsia or late fetal loss: Aspirin plus prophylactic heparin/LMWH reduces complications (severe preeclampsia incidence drops from 15% to 5%).
  4. Thrombotic APS: Therapeutic-dose LMWH (e.g., enoxaparin 1 mg/kg twice daily) with aspirin is recommended.
    Postpartum, women without prior thrombosis receive 6 weeks of prophylactic LMWH, while those with thrombosis resume therapeutic anticoagulation.

Novel Therapeutic Avenues

Rituximab: This anti-CD20 monoclonal antibody targets B-cell-driven aPL production. The RITAPS trial reported improvement in non-criteria manifestations (thrombocytopenia, skin ulcers) in 70% of refractory APS patients.
Eculizumab: A C5 inhibitor prevents membrane attack complex formation. Case studies describe efficacy in CAPS and APS-associated thrombotic microangiopathy.
Defibrotide: This oligonucleotide enhances endothelial protection and fibrinolysis. Small studies show promise in microvascular thrombosis and CAPS.
Coenzyme Q10 (ubiquinol): In a randomized trial, ubiquinol (200 mg/day) improved endothelial function and reduced monocyte tissue factor expression by 30% in APS patients.

Clinical Implications and Future Directions

APS management requires personalized risk assessment. Triple-positive aPL profiles, arterial thrombosis, and CAPS demand aggressive anticoagulation, while non-criteria manifestations may benefit from immunomodulatory agents. Emerging biomarkers, such as anti-domain I β2GPI and anti-phosphatidylserine/prothrombin antibodies, could refine risk stratification. Ongoing research explores adenosine receptor agonists, JAK/STAT inhibitors, and NET-targeted therapies to address unmet needs in APS care.

doi.org/10.1097/CM9.0000000000000705

Was this helpful?

0 / 0